Sherman F. Stinson
Reata Pharmaceuticals (United States)(US)Frederick National Laboratory for Cancer Research(US)National Cancer Institute(US)Center for Cancer Research(US)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, HIV/AIDS drug development and treatment, Cancer therapeutics and mechanisms, HIV Research and Treatment, Carcinogens and Genotoxicity Assessment
Most-Cited Works
- → Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.(1998)408 cited
- → Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.(1998)242 cited
- → Antitumor Benzothiazoles. 8. Synthesis, Metabolic Formation, and Biological Properties of the C- and N-Oxidation Products of Antitumor 2-(4-Aminophenyl)benzothiazoles(1999)226 cited
- → Cyclin-Dependent KinasesInitial Approaches to Exploit a Novel Therapeutic Target(1999)116 cited
- → 13- cis -Retinoic Acid: Inhibition of Bladder Carcinogenesis Induced in Rats by N -Butyl- N -(4-hydroxybutyl)nitrosamine(1977)111 cited
- Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.(2000)